此前数年，吴晓滨一直是百济神州的 核心人物 ，2025年6月 以前，其同时担任总裁、首席运营官兼中国区总经理。目前， 吴晓滨仍担任首席运营官和中国区总经理。 作者：张铃 封图：图虫创意 汪来自2021年4月起担任百济神州全球研发负责人。在此之前，他自 2011 年加入百济神州，担 任过多个研发领导职务，职责逐渐扩大。加入百济神州之前，汪来分别在复旦大学获得理学学士学 位，在德克萨斯大学圣安东尼奥健康科学中心获得博士学位，并于2008年至2011年在位于美国德 克萨斯州达拉斯的生物技术公司Joyant Pharmaceuticals担任研究主管。 据复旦大学校友总会2021年发布的一篇对汪来的专访，汪来从小是个"神童"，14岁就考入复旦， 成为少年大学生，24岁美国博士毕业。博士毕业后，汪来前往美国德州西南医学中心王晓东团队 做博士后。 王晓东是百济神州的创始人之一。2010年，王晓东与汪来讨论，想在中国创建一家生物制药公 司，王晓东非常看好以创新药为方向的中国医药企业的未来。他找到汪来，希望他回国，一起参与 创办百济神州。经过慎重思考，34岁时，汪来决定回国，而且是带着全家一起回国，后来，他成 为百济神州最重 ...

Group 1 - The company has entered a dual presidency phase with the appointment of Dr. Wang Lai as the new president, alongside the existing president, Dr. Wu Xiaobin [1][3] - Dr. Wang will oversee the company's research and development, business development, and alliance management functions [1] - Dr. Wu will continue in his role as president and COO, responsible for global commercialization, production, and supply chain operations [3] Group 2 - Dr. Wang is a key figure in the company, having led the development of the BTK inhibitor, Zebutinib, which is projected to generate $2.6 billion in sales in 2024, ranking 20th in global oncology drug sales [3] - The success of Zebutinib is attributed to both its therapeutic breakthroughs and effective commercialization strategies [3] - The collaboration between Dr. Wang's R&D team and Dr. Wu's commercialization team has been noted as highly effective [3]

Group 1 - The core point of the article is the appointment of Wang Lai as the new President and Global Head of R&D at BeiGene, effective January 1, 2026, with a significant compensation package [1] - Wang Lai will receive an annual salary of $750,000 (approximately 5.28 million RMB) and is eligible for an annual target bonus equivalent to 75% of his base salary [1] - BeiGene will grant Wang Lai a one-time equity incentive of $10 million in the form of restricted stock units [1] Group 2 - Prior to his appointment, Wang Lai served as the Global Head of R&D at BeiGene since April 2021 and has held various leadership roles in R&D since joining the company in 2011 [2] - Wang Lai has an impressive academic background, having obtained a Bachelor's degree from Fudan University and a Ph.D. from the University of Texas Health Science Center [2] - He was a key leader in the development of the important drug, Zebrutinib, and was encouraged by BeiGene's co-founder, Wang Xiaodong, to return to China to help establish the company [2]

Core Viewpoint - BeiGene announced that Wu Xiaobin remains in his position as President and Chief Operating Officer, while Wang Lai has been appointed as the new President and Global Head of R&D, effective immediately [1] Group 1 - Wu Xiaobin's role in the company has not changed, continuing as President and COO [1] - The board of BeiGene approved the appointment of Wang Lai as President and Global Head of R&D [1] - Wang Lai will oversee the company's research, business development, and management of business alliance relationships [1]

Group 1: Eli Lilly - Eli Lilly has submitted a new oral weight loss drug, orforglipron, for FDA approval, indicating a competitive edge in the weight loss medication market [1] - Participants switching from Novo Nordisk's Wegovy to orforglipron maintained most of their weight loss, with an average rebound of only 0.9 kg [1] Group 2: Fosun Pharma - Fosun Pharma's subsidiary has signed a collaboration agreement with Clavis Bio, which could yield up to $363 million in payments [2] - Clavis Bio will have exclusive global rights (excluding mainland China, Hong Kong, and Macau) for development, production, and commercialization of the selected targets [2] - Fosun Pharma will also gain a minority stake in a new project company established by Clavis Bio for this collaboration [2] Group 3: Baidu - Baidu has announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [3] - The issuance and listing are subject to shareholder approval and regulatory approvals, with specific details yet to be finalized [3] Group 4: BeiGene - BeiGene has appointed Dr. Wang Lai as the new President and Global Head of R&D, reflecting the company's commitment to innovation in drug development [4] - Dr. Wang has been with BeiGene since 2011 and has progressively taken on more responsibilities in R&D leadership [4] Group 5: Junshi Biosciences - Junshi Biosciences announced that major shareholder Shanghai Tanying plans to reduce its stake by up to 2%, equating to approximately 2,053,380 shares [5] - The reduction is scheduled between January 13, 2026, and April 10, 2026, despite the shareholder's long-term confidence in the company's prospects [5]

此次刊发的两项Ⅲ期临床研究成果，分别是玛仕度肽在2型糖尿病患者中的单药治疗研究（DREAMS— 1）和与口服降糖药联合使用的研究（DREAMS—2），前者由南京大学医学院附属鼓楼医院朱大龙教 授团队、山东第一医科大学附属省立医院赵家军教授团队等全国多个临床研究中心团队与信达生物研发 团队联合完成，后者由北京医院郭立新教授团队与中日友好医院张波教授、杨文英教授等全国多个临床 研究中心团队与信达生物研发团队合作完成。 由我国多家研发单位联合完成的两项降糖减重药物Ⅲ期临床研究成果，北京时间18日在线发表于国际科 学顶级学术期刊《自然》（《Nature》）。 （文章来源：人民日报） ...

百济神州(06160)发布公告，2025年12月17日，经百济神州有限公司(以下简称"公司")董事会审议通过， 公司董事会同意聘任公司全球研发负责人汪来博士担任公司总裁，全球研发负责人。聘任生效后，汪来 博士担任公司总裁，全球研发负责人职务，负责管理公司研发、业务拓展以及业务联盟关系管理等职 能。 ...

Core Viewpoint - BeiGene has appointed Dr. Wang Lai as the new President and Global Head of R&D, effective December 17, 2025, following approval by the company's board of directors [1] Group 1 - The board of directors of BeiGene has approved the appointment of Dr. Wang Lai [1] - Dr. Wang Lai will be responsible for managing the company's R&D, business development, and alliance management functions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司關於聘任公司高 級管理人員的公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年12月18日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事王 曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、Corazon (C ...

北京商报讯（记者 丁宁）12月18日晚间，百济神州（688235）发布公告称，12月17日，经公司董事会 审议通过，公司董事会同意聘任公司全球研发负责人汪来担任公司总裁，全球研发负责人。聘任生效 后，汪来担任公司总裁，全球研发负责人职务，负责管理公司研发、业务拓展以及业务联盟关系管理等 职能。 公告显示，汪来自2021年4月起担任百济神州全球研发负责人。在此之前，自2011年加入公司以来，他 担任过多个研发领导职务，职责逐渐扩大。加入公司之前，于2008年至2011年，汪来在位于美国德克萨 斯州达拉斯的生物技术公司Joyant Pharmaceuticals担任研究主管。汪来于1996年获得复旦大学理学学士 学位，于2001年获得德克萨斯大学圣安东尼奥健康科学中心博士学位。 ...